ArticleFrontiers in pharmacology2025
Salvia miltiorrhiza (Danshen) promotes Achilles tendon repair: from network pharmacology prediction to in vivo mechanistic validation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plant-Derived Bioactives in Tendon and Enthesis Biology: An Evidence-Tiered Narrative Review.Nutrients · 2026Review
- CDK4 inhibition by luteolin enhances lenvatinib sensitivity in HCC via Wnt/β-catenin modulation.Cancer cell international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the key bioactive component of Salvia miltiorrhiza (Danshen) for repairing Achilles tendon injury and to elucidate its underlying mechanisms. Methods: A network pharmacology approach was employed to screen for common targets for Danshen in Achilles tendon repair, identifying Tanshinone IIA (Tan IIA) as the key bioactive component. Its targets were then subjected to Protein-Protein Interaction (PPI) and KEGG pathway analyses. Subsequently, a rat model of Achilles tendon injury was established. After a 4-week intervention with Tan IIA, its reparative effects were comprehensively evaluated using histological, biomechanical, immunohistochemical (IHC), and ELISA methods. Results: Network pharmacology predicted that Tan IIA acts through core targets such as AKT1 and EGFR to regulate pathways including PI3K-Akt and MAPK. Conclusion: Tan IIA is the key bioactive component of Salvia miltiorrhiza for repairing Achilles tendon injury. It effectively promotes the structural and functional healing of the tendon by synergistically regulating key processes such as inflammation, matrix remodeling, and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.